A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience

Completed · Phase 2 · Has a placebo group

Conditions studied: Gastroesophageal Reflux Disease

In brief

The purpose of the study is to estimate what effect 4 different doses of AZD3355 will have on the number of reflux episodes, in patients who have GERD and still experience symptoms despite proton pump inhibitor (PPI) treatment.

Key facts

Study ID

NCT01043185

Run by

AstraZeneca

People needed

27

Starts

2009-12-01

Expected to finish

2010-05-01

Last updated by the study team

2011-06-14

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provide informed consent
• History of GERD with persistent symptoms despite treatment with PPI
• Otherwise normal physical health

You may not qualify if…

• History of GERD with symptoms that has not improved at all during treatment with PPI
• Prior surgery of the upper gastrointestinal tract
• History of significant heart disease, cardiovascular, respiratory, hepatic, renal, metabolic, psychiatric or gastrointestinal disorders besides GERD

Where it is running

• Research Site — Oklahoma City, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.